What are the most common mistakes with Mazdutide?
The most common Mazdutide mistakes are treating it as freely available, it's only approved in China currently; titrating too fast; skipping protein during the cut. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for Mazdutide is limited.
Common Mazdutide mistakes
- Treating it as freely available, it's only approved in China currently
- Titrating too fast
- Skipping protein during the cut
Bloodwork worth tracking
- Lipid panel
- ALT/AST
- A1C
References
- Mazdutide in Chinese adults with obesity (Phase 3) — Ji L et al., Nat Med, 2025
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight (GLORY-1) — Ji et al., N Engl J Med, 2025
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity — Ji et al., Nature Communications, 2023
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Mazdutide
Last updated 2026-06-15.